Holen Sie sich die Stockscreener-App
131.46
0.90%
-1.20
Vorhandelsmarkt:
131.00
-0.46
-0.35%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$132.66
Offen:
$132.685
24-Stunden-Volumen:
5.77M
Relative Volume:
0.92
Marktkapitalisierung:
$228.80B
Einnahmen:
$43.11B
Nettoeinkommen (Verlust:
$13.94B
KGV:
16.47
EPS:
7.98
Netto-Cashflow:
$6.78B
1W Leistung:
-0.10%
1M Leistung:
+3.28%
6M Leistung:
-4.75%
1J Leistung:
+16.06%
1-Tages-Spanne:
$130.84
$133.40
1-Wochen-Bereich:
$130.14
$133.40
52-Wochen-Spanne:
$110.86
$140.84
Abbott Laboratories Stock (ABT) Company Profile
Firmenname
Abbott Laboratories
Sektor
Branche
Telefon
(224) 667-6100
Adresse
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Vergleichen Sie ABT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
131.46 | 230.89B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
106.66 | 156.32B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
389.94 | 149.64B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
93.33 | 119.05B | 34.20B | 4.69B | 5.30B | 3.63 |
|
EW
Edwards Lifesciences Corp
|
81.77 | 47.75B | 5.69B | 1.41B | 577.90M | 6.95 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-18 | Hochstufung | Jefferies | Hold → Buy |
| 2025-06-16 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-10-08 | Eingeleitet | Oppenheimer | Outperform |
| 2024-09-19 | Eingeleitet | Piper Sandler | Overweight |
| 2024-07-30 | Herabstufung | Edward Jones | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2023-07-21 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | Bestätigt | Barclays | Overweight |
| 2023-04-20 | Bestätigt | Bernstein | Outperform |
| 2023-04-20 | Bestätigt | JP Morgan | Overweight |
| 2023-04-20 | Bestätigt | Raymond James | Outperform |
| 2023-04-20 | Bestätigt | UBS | Buy |
| 2023-04-20 | Bestätigt | Wolfe Research | Underperform |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2022-10-26 | Eingeleitet | Mizuho | Neutral |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-07-06 | Eingeleitet | Wolfe Research | Underperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-01-27 | Bestätigt | Credit Suisse | Outperform |
| 2022-01-27 | Bestätigt | Morgan Stanley | Overweight |
| 2022-01-27 | Bestätigt | Raymond James | Outperform |
| 2022-01-27 | Bestätigt | UBS | Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-10-27 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | Eingeleitet | Redburn | Neutral |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Neutral |
| 2021-01-28 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Outperform |
| 2020-06-01 | Herabstufung | Goldman | Neutral → Sell |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Neutral |
| 2020-01-02 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-06-13 | Bestätigt | BofA/Merrill | Buy |
| 2019-02-07 | Bestätigt | BofA/Merrill | Buy |
| 2019-01-02 | Herabstufung | Citigroup | Neutral → Sell |
| 2018-11-30 | Hochstufung | Goldman | Neutral → Buy |
| 2018-10-16 | Eingeleitet | Barclays | Overweight |
| 2018-06-27 | Eingeleitet | Bernstein | Outperform |
| 2018-01-30 | Bestätigt | Citigroup | Neutral |
| 2018-01-25 | Bestätigt | Stifel | Buy |
| 2018-01-25 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | Eingeleitet | Evercore ISI | Outperform |
| 2018-01-02 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-01-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-10-19 | Bestätigt | Stifel | Buy |
Alle ansehen
Abbott Laboratories Aktie (ABT) Neueste Nachrichten
Real time social sentiment graph for Abbott LaboratoriesWeekly Gains Report & Risk Controlled Swing Alerts - Newser
Allegro appoints life sciences veteran as Chief Operating Officer to advance osteoarthritis treatment - GlobeNewswire Inc.
Abbott Laboratories stock trend outlook and recovery pathWeekly Trend Summary & Risk Managed Investment Strategies - Newser
Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock - uk.finance.yahoo.com
Tools to assess Abbott Laboratories’s risk profileJuly 2025 Pullbacks & Expert Verified Movement Alerts - Newser
Medtronic wins FDA nod to integrate Abbott’s Instinct sensor with MiniMed 780G - Seeking Alpha
Medtronic gets FDA OK to integrate Minimed with Abbott’s Instinct - BioWorld MedTech
How to track smart money flows in Abbott LaboratoriesJuly 2025 Update & Expert Curated Trade Ideas - Newser
How to escape a deep drawdown in Abbott LaboratoriesJuly 2025 Highlights & Real-Time Market Sentiment Alerts - Newser
Stock Analysis | Abbott Laboratories OutlookTechnical Caution Amid Optimistic Fundamentals and Mixed Analyst Views - AInvest
How Abbott Laboratories (ABT) Affects Rotational Strategy Timing - news.stocktradersdaily.com
How to integrate Abbott Laboratories into portfolio analysis toolsPortfolio Growth Summary & Advanced Swing Trade Entry Alerts - Newser
Can technical indicators confirm Abbott Laboratories’s reversalJuly 2025 PreEarnings & Weekly High Momentum Picks - Newser
Is Abbott Laboratories stock poised for growthBond Market & Long-Term Safe Investment Plans - Newser
How Is Abbott Laboratories' Stock Performance Compared to Other Medical Devices Stocks? - MSN
Is now a turning point for Abbott Laboratories2025 Risk Factors & Expert Curated Trade Setups - Newser
Is Abbott Laboratories stock undervalued right nowQuarterly Profit Review & Expert Curated Trade Setup Alerts - خودرو بانک
Measuring Abbott Laboratories’s beta against major indicesWeekly Investment Report & Weekly Hot Stock Watchlists - Newser
What earnings revisions data tells us about Abbott LaboratoriesJuly 2025 Update & Consistent Profit Alerts - Newser
Price action breakdown for Abbott LaboratoriesShort Setup & AI Powered Market Trend Analysis - Newser
Real time pattern detection on Abbott Laboratories stockQuarterly Portfolio Review & Low Volatility Stock Suggestions - Newser
Abbott Laboratories Shows Early Signs of Technical Strength getLinesFromResByArray error: size == 0 - thegnnews.com
Jim Cramer Shares Little Known Potential Catalyst For Abbott Laboratories (ABT) - MSN
Does Abbott Laboratories show high probability of reboundMarket Trend Summary & Entry Point Confirmation Alerts - Newser
Does Abbott Laboratories fit your quant trading modelWeekly Trend Summary & Low Risk High Win Rate Stock Picks - Newser
What MACD and RSI say about Abbott LaboratoriesWeekly Gains Summary & Long-Term Capital Growth Ideas - Newser
What institutional flow reveals about Abbott LaboratoriesMarket Activity Report & Reliable Volume Spike Alerts - Newser
Abbott Laboratories CEO warns tariffs are here to stay, points to new US investments [Video] - AOL.com
Precision Trading with Abbott Laboratories (ABT) Risk Zones - news.stocktradersdaily.com
A Look at Abbott Laboratories’s Valuation Following Strong Medical Device Launches and Regulatory Milestones - simplywall.st
Abbott’s Possible Pokeno Acquisition Might Change the Case for Investing in Abbott Laboratories (ABT) - Yahoo Finance
Ranking Abbott Laboratories among high performing stocks via toolsPortfolio Update Report & Free Risk Controlled Daily Trade Plans - Newser
Price momentum metrics for Abbott Laboratories explainedJuly 2025 EndofMonth & Risk Controlled Daily Trade Plans - Newser
IoT in Healthcare Market to See Thriving Worldwide | Abbott Laboratories, Philips, Medtronic - openPR.com
Using Bollinger Bands to evaluate Abbott Laboratories2025 Macro Impact & Breakout Confirmation Trade Signals - Newser
Can a trend reversal in Abbott Laboratories lead to recoveryJuly 2025 Trends & Low Risk Profit Maximizing Plans - Newser
Fibonacci Support Holding Strong in Abbott LaboratoriesRecession Risk & Growth Oriented Trading Recommendations - beatles.ru
St. Jude Medical delivers sales growth for Abbott Labs - Star Tribune
Abbott Laboratories: Is The Growth in Continuous Glucose Monitoring (CGM) & Ketone Monitoring Here To Stay? - Smartkarma
Applying chart zones and confluence areas to Abbott Laboratories2025 Institutional Moves & Weekly High Potential Alerts - Newser
Live market analysis of Abbott Laboratories2025 Price Action Summary & Comprehensive Market Scan Insights - Newser
Finanzdaten der Abbott Laboratories-Aktie (ABT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.10%
0.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):